In the news today ...... Let's hope this is a great sign for our men's future health 👍😊
This has been described as a milestone as it could also halt tumour growth I many men with treatment-resistant prostate cancer.
A third of 49 men had tumours that stopped growing, with numbers of circulating tumour class in the blood falling and PSA levels plunged by up to 96%
Full article on cancer research uk website link further down
A trial of olaparib for prostate cancer that has spread and has got worse after hormone therapy and chemotherapy (TOPARP)
A trial to see if olaparib helps men with prostate cancer that has got worse despite treatment with hormone therapy and chemotherapy drugs called taxanes. The trial is supported by Cancer Research UK.
Doctors can treat prostate cancer that has spread with chemotherapy and hormone therapy. But prostate cancer may stop responding to these standard treatments . Doctors are looking for new treatments to help men in this situation. In this trial they are looking at a drug called olaparib.
Every cell contains DNA. It is the genetic information that controls how cells behave. In cancer cells, the DNA is damaged and they rely heavily on an enzyme called PARP-1 to repair it.
Olaparib stops PARP-1 from working. If PARP-1 doesn’t work, cancer cells can’t repair themselves and they die.
Olaparib has been looked at in trials for other types of cancer, both on its own and alongside other drugs. The aims of this trial are to
See if olaparib helps men with prostate cancer that is not responding to hormone therapy
Find out if some men are more likely to benefit from olaparib than others
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann de Bono
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Institute of Cancer Research (ICR)
NIHR Clinical Research Network: Cancer
The Royal Marsden NHS Foundation Trust
This is Cancer Research UK trial number CRUK/11/029http://www.cancerresearc...-and-chemotherapy-toparp